203 related articles for article (PubMed ID: 22189598)
1. A mixture of oleic, erucic and conjugated linoleic acids modulates cerebrospinal fluid inflammatory markers and improve somatosensorial evoked potential in X-linked adrenoleukodystrophy female carriers.
Cappa M; Bizzarri C; Petroni A; Carta G; Cordeddu L; Valeriani M; Vollono C; De Pasquale L; Blasevich M; Banni S
J Inherit Metab Dis; 2012 Sep; 35(5):899-907. PubMed ID: 22189598
[TBL] [Abstract][Full Text] [Related]
2. Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect.
Deon M; Garcia MP; Sitta A; Barschak AG; Coelho DM; Schimit GO; Pigatto M; Jardim LB; Wajner M; Giugliani R; Vargas CR
Metab Brain Dis; 2008 Mar; 23(1):43-9. PubMed ID: 18026827
[TBL] [Abstract][Full Text] [Related]
3. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil.
Poulos A; Gibson R; Sharp P; Beckman K; Grattan-Smith P
Ann Neurol; 1994 Nov; 36(5):741-6. PubMed ID: 7979219
[TBL] [Abstract][Full Text] [Related]
4. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy.
Aubourg P; Adamsbaum C; Lavallard-Rousseau MC; Rocchiccioli F; Cartier N; Jambaqué I; Jakobezak C; Lemaitre A; Boureau F; Wolf C
N Engl J Med; 1993 Sep; 329(11):745-52. PubMed ID: 8350883
[TBL] [Abstract][Full Text] [Related]
5. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".
van Geel BM; Assies J; Haverkort EB; Koelman JH; Verbeeten B; Wanders RJ; Barth PG
J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):290-9. PubMed ID: 10449548
[TBL] [Abstract][Full Text] [Related]
6. A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.
Ahmed MA; Kartha RV; Brundage RC; Cloyd J; Basu C; Carlin BP; Jones RO; Moser AB; Fatemi A; Raymond GV
Br J Clin Pharmacol; 2016 Jun; 81(6):1058-66. PubMed ID: 26836218
[TBL] [Abstract][Full Text] [Related]
7. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy.
Kemp S; Valianpour F; Denis S; Ofman R; Sanders RJ; Mooyer P; Barth PG; Wanders RJ
Mol Genet Metab; 2005 Feb; 84(2):144-51. PubMed ID: 15670720
[TBL] [Abstract][Full Text] [Related]
8. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.
Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR
J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542
[TBL] [Abstract][Full Text] [Related]
9. "Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy.
Moser HW; Moser AB; Hollandsworth K; Brereton NH; Raymond GV
J Mol Neurosci; 2007 Sep; 33(1):105-13. PubMed ID: 17901554
[TBL] [Abstract][Full Text] [Related]
10. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil.
Moser HW; Raymond GV; Lu SE; Muenz LR; Moser AB; Xu J; Jones RO; Loes DJ; Melhem ER; Dubey P; Bezman L; Brereton NH; Odone A
Arch Neurol; 2005 Jul; 62(7):1073-80. PubMed ID: 16009761
[TBL] [Abstract][Full Text] [Related]
11. Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible?
Cappa M; Bizzarri C; Giannone G; Aiello C; Di Biase A
J Endocrinol Invest; 2011 Nov; 34(10):753-6. PubMed ID: 21399389
[TBL] [Abstract][Full Text] [Related]
12. Dietary management of X-linked adrenoleukodystrophy.
Moser HW; Borel J
Annu Rev Nutr; 1995; 15():379-97. PubMed ID: 8527226
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of very long-chain fatty acids levels in X-linked adrenoleukodystrophy, treated with haematopoietic stem cell transplantation and Lorenzo's Oil.
Stradomska TJ; Drabko K; Moszczyńska E; Tylki-Szymańska A
Folia Neuropathol; 2014; 52(2):159-63. PubMed ID: 25118901
[TBL] [Abstract][Full Text] [Related]
14. Adrenoleukodystrophy and the mitochondrial connection: clues for supplementing Lorenzo's oil.
Moraes CT
Brain; 2013 Aug; 136(Pt 8):2339-41. PubMed ID: 23842565
[No Abstract] [Full Text] [Related]
15. Lorenzo's oil inhibits ELOVL1 and lowers the level of sphingomyelin with a saturated very long-chain fatty acid.
Sassa T; Wakashima T; Ohno Y; Kihara A
J Lipid Res; 2014 Mar; 55(3):524-30. PubMed ID: 24489110
[TBL] [Abstract][Full Text] [Related]
16. Treatment of X-linked adrenoleukodystrophy with Lorenzo's oil.
Moser HW
J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):279-80. PubMed ID: 10449544
[No Abstract] [Full Text] [Related]
17. Lorenzo's oil: a reassessment.
Poulos A; Robertson EF
Med J Aust; 1994 Mar; 160(6):315-7. PubMed ID: 8133809
[No Abstract] [Full Text] [Related]
18. Lorenzo's oil: advances in the treatment of neurometabolic disorders.
Ferri R; Chance PF
Arch Neurol; 2005 Jul; 62(7):1045-6. PubMed ID: 16009756
[No Abstract] [Full Text] [Related]
19. Positive effects with Lorenzo's oil.
Siva N
Lancet Neurol; 2005 Sep; 4(9):529. PubMed ID: 16136703
[No Abstract] [Full Text] [Related]
20. A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil.
Basu C; Ahmed MA; Kartha RV; Brundage RC; Raymond GV; Cloyd JC; Carlin BP
J Biopharm Stat; 2016; 26(6):1025-1039. PubMed ID: 27547896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
